142 related articles for article (PubMed ID: 29578154)
1. Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer: Does the age matter?
Zhao CJ; Li S; Liu Q
J Cancer Res Ther; 2018; 14(Supplement):S79-S84. PubMed ID: 29578154
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?
Zhao C; Li S; Liu Q
J Chemother; 2016 Aug; 28(4):321-7. PubMed ID: 26239366
[TBL] [Abstract][Full Text] [Related]
3. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
4. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
5. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Leal F; Ferreira FP; Sasse AD
Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
[TBL] [Abstract][Full Text] [Related]
6. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
8. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
9. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
10. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
11. Standard chemotherapy with cetuximab for treatment of colorectal cancer.
Li XX; Liang L; Huang LY; Cai SJ
World J Gastroenterol; 2015 Jun; 21(22):7022-35. PubMed ID: 26078581
[TBL] [Abstract][Full Text] [Related]
12. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cremolini C; Antoniotti C; Pietrantonio F; Berenato R; Tampellini M; Baratelli C; Salvatore L; Marmorino F; Borelli B; Nichetti F; Bironzo P; Sonetto C; Bartolomeo MD; Braud F; Loupakis F; Falcone A; Di Maio M
Cancer Res Treat; 2017 Jul; 49(3):834-845. PubMed ID: 27857020
[TBL] [Abstract][Full Text] [Related]
13. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Landre T; Maillard E; Taleb C; Ghebriou D; Guetz GD; Zelek L; Aparicio T
Int J Colorectal Dis; 2018 Aug; 33(8):1125-1130. PubMed ID: 29680896
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer.
Yoshida Y; Kaneko M; Narukawa M
Int J Clin Oncol; 2020 May; 25(5):851-860. PubMed ID: 31950377
[TBL] [Abstract][Full Text] [Related]
16. The role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.
Wang CW; Fang XH
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1725-32. PubMed ID: 27212163
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL; Shi Q; Goey KKH; Meyers J; Heinemann V; Diaz-Rubio E; Aranda E; Falcone A; Green E; de Gramont A; Sargent DJ; Punt CJA; Koopman M
Eur J Cancer; 2018 Mar; 91():99-106. PubMed ID: 29353165
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Eltawil KM; Renfrew PD; Molinari M
HPB (Oxford); 2012 Apr; 14(4):260-8. PubMed ID: 22404265
[TBL] [Abstract][Full Text] [Related]
20. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.
Du J; Mao Y; Liu M; Tie Y; Huang H; Zhao J; Xiang Z; Luo D
Oncotarget; 2017 Nov; 8(60):102413-102419. PubMed ID: 29254256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
